For use under medical supervision
M., Basaria, S., Boden, W
Collectively, numerous retrospective and large database studies have identified potential benefits of GLP-1RA in ocular disease, indicating a need for prospective trials to more definitively identify protective effects and integrate this medication class into the ophthalmology toolbox
Conversely, patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 should not take semaglutide
[10] [11] Symptoms warranting thyroid function assessment include unexplained fatigue, weight changes beyond those expected from GLP-1 therapy, changes in heart rate, mood alterations, temperature intolerance, or changes in bowel habits